387 related articles for article (PubMed ID: 26727332)
1. Recurrences and toxicity after adjuvant vaginal brachytherapy in Stage I-II endometrial cancer: A monoinstitutional experience.
Perrucci E; Lancellotta V; Bini V; Zucchetti C; Mariucci C; Montesi G; Saccia S; Palumbo I; Aristei C
Brachytherapy; 2016; 15(2):177-84. PubMed ID: 26727332
[TBL] [Abstract][Full Text] [Related]
2. Intravaginal brachytherapy alone for intermediate-risk endometrial cancer.
Alektiar KM; Venkatraman E; Chi DS; Barakat RR
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):111-7. PubMed ID: 15850910
[TBL] [Abstract][Full Text] [Related]
3. Single-institutional outcomes of adjuvant brachytherapy for Stage I endometrial cancer-Are outcomes consistent with randomized studies?
Dohopolski MJ; Horne ZD; Gebhardt BJ; Glaser SM; Edwards RP; Kelley JL; Comerci JT; Olawaiye AB; Courtney-Brooks M; Berger JL; Sukumvanich P; Beriwal S
Brachytherapy; 2018; 17(3):564-570. PubMed ID: 29426745
[TBL] [Abstract][Full Text] [Related]
4. [High dose rate vaginal brachytherapy in endometrial cancer after surgery].
Moreau-Claeys MV; Brunaud C; Hoffstetter S; Buchheit I; Peiffert D
Cancer Radiother; 2011 Jun; 15(3):169-75. PubMed ID: 21237693
[TBL] [Abstract][Full Text] [Related]
5. Do vaginal recurrence rates differ among adjuvant vaginal brachytherapy regimens in early-stage endometrial cancer?
Ager BJ; Francis SR; Do OA; Huang YJ; Soisson AP; Dodson MK; Werner TL; Sause WT; Grant JD; Gaffney DK
Brachytherapy; 2019; 18(4):453-461. PubMed ID: 31005603
[TBL] [Abstract][Full Text] [Related]
6. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial.
Nout RA; Smit VT; Putter H; Jürgenliemk-Schulz IM; Jobsen JJ; Lutgens LC; van der Steen-Banasik EM; Mens JW; Slot A; Kroese MC; van Bunningen BN; Ansink AC; van Putten WL; Creutzberg CL;
Lancet; 2010 Mar; 375(9717):816-23. PubMed ID: 20206777
[TBL] [Abstract][Full Text] [Related]
7. Intravaginal high-dose-rate brachytherapy for Stage IB (FIGO Grade 1, 2) endometrial cancer.
Alektiar KM; McKee A; Venkatraman E; McKee B; Zelefsky MJ; Mychalczak BR; Hoskins WJ; Barakat RR
Int J Radiat Oncol Biol Phys; 2002 Jul; 53(3):707-13. PubMed ID: 12062616
[TBL] [Abstract][Full Text] [Related]
8. Local recurrence in high-risk node-negative stage I endometrial carcinoma treated with postoperative vaginal vault brachytherapy.
Ng TY; Perrin LC; Nicklin JL; Cheuk R; Crandon AJ
Gynecol Oncol; 2000 Dec; 79(3):490-4. PubMed ID: 11104626
[TBL] [Abstract][Full Text] [Related]
9. EROS 2.0 study: evaluation of two interventional radiotherapy (brachytherapy) schedules for endometrial cancer: a comparison of late vaginal toxicity rates.
Lancellotta V; Macchia G; Dinapoli N; Autorino R; Campitelli M; Nardangeli A; Salvati A; Fionda B; Casà C; Cornacchione P; Rovirosa A; Kovács G; Morganti AG; Ferrandina MG; Gambacorta MA; Tagliaferri L
Radiol Med; 2022 Mar; 127(3):341-348. PubMed ID: 35092552
[TBL] [Abstract][Full Text] [Related]
10. Low-dose adjuvant vaginal cylinder brachytherapy for early-stage non-endometrioid endometrial cancer: recurrence risk and survival outcomes.
Smart A; Buscariollo D; Alban G; Buzurovic I; Cheng T; Pretz J; Krechmer B; King M; Lee L
Int J Gynecol Cancer; 2020 Dec; 30(12):1908-1914. PubMed ID: 32655012
[TBL] [Abstract][Full Text] [Related]
11. Predictive factors of recurrence following adjuvant vaginal cuff brachytherapy alone for stage I endometrial cancer.
Dunn EF; Geye H; Platta CS; Gondi V; Rose S; Bradley KA; Anderson BM
Gynecol Oncol; 2014 Jun; 133(3):494-8. PubMed ID: 24657301
[TBL] [Abstract][Full Text] [Related]
12. Excellent long-term survival and absence of vaginal recurrences in 332 patients with low-risk stage I endometrial adenocarcinoma treated with hysterectomy and vaginal brachytherapy without formal staging lymph node sampling: report of a prospective trial.
Eltabbakh GH; Piver MS; Hempling RE; Shin KH
Int J Radiat Oncol Biol Phys; 1997 May; 38(2):373-80. PubMed ID: 9226326
[TBL] [Abstract][Full Text] [Related]
13. External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma--a prospective randomized study.
Sorbe B; Horvath G; Andersson H; Boman K; Lundgren C; Pettersson B
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1249-55. PubMed ID: 21676554
[TBL] [Abstract][Full Text] [Related]
14. Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer.
Randall ME; Filiaci V; McMeekin DS; von Gruenigen V; Huang H; Yashar CM; Mannel RS; Kim JW; Salani R; DiSilvestro PA; Burke JJ; Rutherford T; Spirtos NM; Terada K; Anderson PR; Brewster WR; Small W; Aghajanian CA; Miller DS
J Clin Oncol; 2019 Jul; 37(21):1810-1818. PubMed ID: 30995174
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant high dose rate vaginal brachytherapy as treatment of stage I and II endometrial carcinoma.
Horowitz NS; Peters WA; Smith MR; Drescher CW; Atwood M; Mate TP
Obstet Gynecol; 2002 Feb; 99(2):235-40. PubMed ID: 11814503
[TBL] [Abstract][Full Text] [Related]
16. Impact of different adjuvant radiotherapy modalities on women with early-stage intermediate- to high-risk endometrial cancer.
Jin M; Hou X; Sun X; Zhang Y; Hu K; Zhang F
Int J Gynecol Cancer; 2019 Oct; 29(8):1264-1270. PubMed ID: 31320487
[TBL] [Abstract][Full Text] [Related]
17. Postoperative vaginal brachytherapy alone is the treatment of choice for grade 1-2, stage IC endometrial cancer.
Cengiz M; Singh AK; Grigsby PW
Int J Gynecol Cancer; 2005; 15(5):926-31. PubMed ID: 16174247
[TBL] [Abstract][Full Text] [Related]
18. Is there a role for a brachytherapy vaginal cuff boost in the adjuvant management of patients with uterine-confined endometrial cancer?
Greven KM; D'Agostino RB; Lanciano RM; Corn BW
Int J Radiat Oncol Biol Phys; 1998 Aug; 42(1):101-4. PubMed ID: 9747826
[TBL] [Abstract][Full Text] [Related]
19. Vaginal high dose rate brachytherapy alone in patients with intermediate- to high-risk stage I endometrial carcinoma after radical surgery.
Atahan IL; Ozyar E; Yildiz F; Ozyigit G; Genc M; Ulger S; Usubutun A; Köse F; Yuce K; Ayhan A
Int J Gynecol Cancer; 2008; 18(6):1294-9. PubMed ID: 18284452
[TBL] [Abstract][Full Text] [Related]
20. The role of vaginal brachytherapy in the treatment of surgical stage I papillary serous or clear cell endometrial cancer.
Barney BM; Petersen IA; Mariani A; Dowdy SC; Bakkum-Gamez JN; Haddock MG
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):109-15. PubMed ID: 22543202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
